A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof

(19)

(11)

EP 2 017 269 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 A2)

(48)	Corrigendum issued on:
	30.09.2009 Bulletin 2009/40

(88)	Date of publication A3:
	10.06.2009 Bulletin 2009/24

(43)	Date of publication:
	21.01.2009 Bulletin 2009/04

(21)	Application number: 08007622.7

(22)	Date of filing: 19.07.1999

(27)	Previously filed application: 19.07.1999 EP 03029709

(51)

International Patent Classification (IPC):

C07D 277/24^(2006.01)
C07D 277/30^(2006.01)
C07D 277/40^(2006.01)
A61K 31/425^(2006.01)

C07D 277/28^(2006.01)
C07D 277/36^(2006.01)
C07D 277/42^(2006.01)

(84)	Designated Contracting States:
	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
	Designated Extension States:
	RO SI

(30)

Priority:

20.07.1998 US 119345
04.06.1999 US 326093

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	03029709.7 / 1418174
	99934143.1 / 1097148

(71)	Applicant: ABBOTT LABORATORIES
	Abbott Park, IL 60064-6008 (US)

(72)	Inventors:
	Bauer, John F. Lake Bluff, IL 60044 (US) Saleki-Gerhardt, Azita Libertyville, IL 60048 (US) Chemburkar, Sanjay R. Gurnee, IL 60031 (US) Patel, Ketan Arlington Heights, IL 60004 (US) Spiwek, Harry O. Kenosha, WI 53142 (US)

(74)	Representative: Modiano, Micaela Nadia et al
	Modiano Josif Pisanty & Staub Ltd Thierschstrasse 11 80538 München 80538 München (DE)


	Remarks:
	This application was filed on 18-04-2008 as a divisional application to the application mentioned under INID code 62.

(54)	A pharmaceutical composition comprising form II crystalline Ritonavir and a preparation thereof

(57) This Application concerns the use of Form II crystalline ritonavir as a pharmaceutical agent, as well as methods of preparing pharmaceutical compositions, which methods employ Form II crystalline ritonavir. The Application further concerns methods for obtaining Form I crystalline ritonavir, which methods employ Form II crystalline ritonavir.